Articles related to BLEEDING/BLOOD DISORDERS

“The idea of preserving and reducing thrombosis without increasing bleeding is very, very exciting.” — Roxana Mehran, MD, SCAI 2025

The primary study outcome was a composite of serious bleeding events leading to hospitalization. Secondary study outcomes included composites of stroke or systemic embolism.

First-line treatment with IV iron dextran is the cost-effective strategy for managing IDA in women with HMB at commonly accepted willingness-to-pay thresholds.

Thrombotic events occurred earlier with Andexxa than usual care (median of 3.5 days vs 16 days). Fifty-three percent of Andexxa-treated patients who experienced a thrombotic event had the event during the first 3 days.

Prior to CDC’s Sickle Cell Data Collection program, the actual number of Americans living with sickle cell disease was unknown, with current estimates of 100,000 patients based on systematic data collection efforts now at risk.

Vaginal fluid collection via tampon under clinical supervision followed by bisulfite conversion and long-probe quantitative amplified signal assays for methylated DNA marker analysis.